• Skip to primary navigation
  • Skip to content
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

CardioCell adds Stony Brook University to sites conducting phase IIa trial

March 12, 2015

News


Mar 12, 2015

CardioCell adds Stony Brook University to sites conducting phase IIa trial

CenterWatch logo 2CardioCell, a Stemedica Cell Technologies subsidiary that designs allogeneic stem-cell therapies for cardiovascular indications, has expanded patient recruitment to Stony Brook University’s Heart Institute for its phase IIa clinical trial for chronic heart failure (HF). READ FULL ARTICLE

Media Coverage,  News

Reader Interactions

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in